Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Dietary Bifidobacterium lactis (HN019) Enhances Resistance to Oral Salmonella typhimurium Infection in Mice

  • 2000-04
  • Microbiology and Immunology 44(4)
    • Q. Shu
    • Hai-Mei Lin
    • K. Rutherfurd
    • S. Fenwick
    • J. Prasad
    • P. Gopal
    • H. Gill

Abstract

The ability of a newly identified probiotic lactic acid bacterial strain, Bifidobacterium lactis (HN019), to confer protection against Salmonella typhimurium was investigated in BALB/c mice. Feeding mice with B. lactis conferred a significant degree of protection against single or multiple oral challenge with virulent S. typhimurium, in comparison to control mice that did not receive B. lactis. Protection included a ten-fold increase in survival rate, significantly higher post-challenge food intake and weight gain, and reduced pathogen translocation to visceral tissues (spleen and liver). Furthermore, the degree of pathogen translocation showed a significant inverse correlation with splenic lymphocyte proliferative responses to mitogens, blood and peritoneal cell phagocytic activity and intestinal mucosal anti-S. typhimurium antibody titers in infected mice; all of these immune parameters were enhanced in mice fed B. lactis. Together, these results suggest that dietary B. lactis can provide a significant degree of protection against Salmonella infection by enhancing various parameters of immune function that are relevant to the immunological control of salmonellosis. Thus dietary supplementation with B. lactis provides a unique opportunity for developing immune-enhancing probiotic dairy food products with proven health benefits.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium lactis HN019Enhanced Lymphocyte ProliferationBeneficial
Moderate
Bifidobacterium lactis HN019Improved Cell Survival RatesBeneficial
Large
Bifidobacterium lactis HN019Increased Intestinal Mucosal Anti-Salmonella Typhimurium Antibody TitersBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Pathogen Translocation to Visceral TissuesBeneficial
Large
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Join Our Community
Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.